Pharma Stock Sees Significant Premarket Action To Start The Week

By: Tomas Ronolski - AllPennyStocks.com News

Monday, April 25, 2022

A small pharmaceutical company is seeing its shares bid up premarket after the company announced that “it has filed a provisional patent application in the United States covering the recently communicated mRNA molecules found in pre-clinical trials to be effective at destroying cancer cells grown in culture,” according to the release. This key event is set to have shares of Sunshine Biopharma Inc. (Nasdaq:SBFM) open much higher on Monday.

Sunshine Biopharma Inc. is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).

Traders appear to be extremely optimistic on the news as shares are currently bid up in premarket action at $4.37/share (+31.23% implied open for sellers) at the time of writing. It’ll be exciting to see how things shake out at the opening bell!

Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.